Discounted Cash Flow
Amneal Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | $1.0b | $-1.7m | $139.4m | -0.2% | — |
| 2018 | $1.7b (60.9%) | $32.8m (2053.1%) | $167.1m (19.9%) | 2.0% (1314.0%) | $-0.16 |
| 2019 | $1.6b (-2.2%) | $241.7m (637.8%) | $-45.5m (-127.2%) | 14.9% (654.4%) | $-2.74 (-1612.5%) |
| 2020 | $2.0b (22.5%) | $22.5m (-90.7%) | $22.5m (149.4%) | 1.1% (-92.4%) | $0.62 (122.6%) |
| 2021 | $2.1b (5.1%) | $-9.5m (-142.5%) | $194.1m (763.4%) | -0.5% (-140.4%) | $0.07 (-88.7%) |
| 2022 | $2.2b (5.7%) | $125.2m (1412.0%) | $18.7m (-90.4%) | 5.7% (1341.6%) | $-1.69 (-2511.4%) |
| 2023 | $2.4b (8.2%) | $-35.3m (-128.2%) | $302.4m (1517.5%) | -1.5% (-126.0%) | $-0.28 (83.6%) |
| 2024 | $2.8b (16.7%) | $-43.0m (-21.9%) | $243.2m (-19.6%) | -1.5% (-4.5%) | $-0.24 (13.6%) |
| 2025 | $3.0b (8.0%) | $-55.9m (-29.9%) | $269.9m (11.0%) | -1.9% (-20.2%) | $0.41 (270.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.